Investment Rating - The report maintains an "Add" rating for the company [5] Core Views - The company demonstrates resilience in performance despite industry challenges, with profit margins expected to improve through quality enhancement and efficiency [2][9] - The company has actively closed 1,078 stores in 2024, primarily in the second half of the year, which has had a short-term impact on revenue growth but is anticipated to enhance profitability in the long run [2][9] - The company plans to increase cash dividends to enhance shareholder returns, distributing a total of 788 million yuan in cash dividends in 2024, which represents 51.56% of net profit [2] Financial Performance Summary - In 2024, the company achieved total revenue of 24.062 billion yuan, with a year-on-year growth of 6.53%, and a net profit of 1.529 billion yuan, reflecting an 8.26% increase [1][4] - For Q1 2025, the company reported revenue of 6.009 billion yuan, with a net profit of 449 million yuan, marking a year-on-year growth of 10.51% [1] - The company expects to achieve net profits of 1.759 billion yuan, 2.025 billion yuan, and 2.297 billion yuan for the years 2025, 2026, and 2027 respectively, with corresponding PE ratios of 19, 16, and 14 [9][12] Market Position and Strategy - The company has a well-established specialized store network, with a focus on regional expansion, having opened 2,512 new stores in 2024 [9] - The company has embraced online new retail, generating online revenue of 2.127 billion yuan in 2024, with O2O contributing 1.721 billion yuan [9] - The company continues to enhance its digital transformation and supply chain optimization, which is expected to drive profitability improvements [2][9]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company demonstrates robust performance growth, showcasing its refined management capabilities. In 2024, the company achieved a revenue of 24.062 billion yuan (up 6.53% year-on-year) and a net profit attributable to shareholders of 1.529 billion yuan (up 8.26% year-on-year) [2] - The company has seen steady growth in its retail and franchise distribution businesses, with the online O2O business growing rapidly. In 2024, retail revenue reached 21.188 billion yuan (up 4.97% year-on-year), and the O2O segment contributed 1.721 billion yuan, growing 23.02% year-on-year [5] - The company is focused on cost reduction and efficiency improvement while maintaining a steady expansion pace. As of the end of 2024, the total number of stores reached 14,684, with a net increase of 1,434 stores year-on-year [5] Summary by Relevant Sections Financial Performance - In Q1 2025, the company reported a revenue of 6.009 billion yuan (up 0.64% year-on-year) and a net profit of 449 million yuan (up 10.51% year-on-year) [2] - The gross margin for 2024 was 40.12%, and for Q1 2025, it was 39.64%, indicating a slight increase year-on-year [5] Business Segments - The company’s franchise and distribution business achieved a revenue of 2.107 billion yuan in 2024 (up 11.34% year-on-year) [5] - The company has strengthened its prescription drug services and expanded its product offerings, including functional and non-functional food and daily necessities [5] Future Projections - The company’s projected net profits for 2025, 2026, and 2027 are 1.755 billion yuan, 1.992 billion yuan, and 2.245 billion yuan, respectively [7] - The earnings per share (EPS) for the same years are expected to be 1.45 yuan, 1.64 yuan, and 1.85 yuan [7]

Investment Rating - The report maintains a positive investment rating for the healthcare sector, particularly focusing on specific companies and segments within the industry [3]. Core Insights - The report emphasizes the recovery of medical device tenders and highlights investment opportunities in segments such as blood dialysis and ultrasound, with a focus on domestic replacements [1][2]. - It suggests that leading companies in the chain pharmacy sector are likely to increase market share due to the exit of smaller players [1]. - The report identifies several key areas for investment, including innovative drugs, CXO services, traditional Chinese medicine, vaccines, and medical devices, among others [1]. Summary by Sections 1. CXO Sector - The CXO sector is expected to see valuation recovery due to supportive innovation policies and a reduction in geopolitical risks [7]. 2. Innovative Drugs - The report notes a slight increase in the A-share chemical preparation sector and highlights recent approvals for innovative drugs, suggesting a focus on ongoing R&D progress [12][67]. 3. Traditional Chinese Medicine - The performance of the traditional Chinese medicine sector has lagged behind broader market indices, indicating potential for future growth [20]. 4. Blood Products - The report highlights the strong pricing power of manufacturers in the blood products sector, driven by increased demand for immunoglobulin products [22]. 5. Vaccine Sector - The vaccine sector is facing challenges due to low birth rates, but there are opportunities in specific areas such as HPV vaccines [26]. 6. Upstream Pharmaceutical Supply Chain - The report suggests focusing on companies with strong brand recognition and overseas growth potential in the chemical and biological reagent sectors [28]. 7. IVD Sector - The IVD sector is expected to benefit from the implementation of centralized procurement policies, which may accelerate domestic replacements [31]. 8. Medical Devices - The report recommends attention to the domestic continuous glucose monitoring (CGM) market, particularly in relation to GLP-1 drugs [37]. 9. Medical Services - The report suggests focusing on eye and dental medical service companies, anticipating a boost from consumer stimulus policies [42]. 10. Offline Pharmacies - The report indicates that leading pharmacy chains are stabilizing, with a recommendation to focus on companies with strong supply chain capabilities [45]. 11. Raw Materials - The report emphasizes the importance of quality and cost management in the raw materials sector, suggesting a focus on companies with strong product capabilities [48]. 12. Innovative Instruments - The report highlights the potential for AI applications in the medical device sector, particularly in surgical navigation and pathology screening [51]. 13. Instrument Equipment - The report notes that the scientific instrument sector is expected to recover as demand improves and more domestic support policies are introduced [56]. 14. Low-value Consumables - The report suggests that the low-value consumables sector may see investment opportunities as the industry cycle improves [59].

Investment Rating - The industry investment rating is optimistic [1] Core Viewpoints - The industry is undergoing a clearing process, with leading companies recovering profitability [2][3] - The overall performance of the chain pharmacy sector is expected to improve in 2025, with a recovery in valuations observed in Q1 2025 [11] - The market is witnessing a shift towards a higher proportion of franchise stores, indicating a trend towards asset-light expansion models [24][29] Summary by Sections Industry Overview - The chain pharmacy sector is experiencing accelerated store closures and slowed openings, with a significant increase in the proportion of franchise stores from 9% in 2020 to 28% in Q1 2025 [24][29] - The market is expected to see a continued increase in the market share of leading companies due to industry consolidation [30] Financial Performance - In Q1 2025, leading companies are expected to see a significant recovery in net profit margins, following a period of adjustment in 2024 [35] - The overall revenue growth rate for the pharmacy sector has declined significantly in 2024, but a recovery in profit growth is anticipated in 2025 due to improved consumer spending and the implementation of coordinated healthcare policies [42] Investment Recommendations - The report recommends investing in leading pharmacy companies with superior management capabilities and quick category adjustments to mitigate the downward pressure on industry profitability. Specific recommendations include Dazhenglin, Yifeng Pharmacy, and Laobaixing, with a focus on Yixin Hall, Jianzhijia, and Shuyupingmin [4][58]

不仅仅是创新药，低迷数年的院外医药赛道也正重新成为公募基金卡位时代的新机会。 券商中国记者注意到，随着关税因素促使内需消费成为公募基金二季度挖掘股票的核心考量，叠加院外医药市 场复苏，今年四月底开始，易方达、广发、华夏、平安基金等多家头部公募基金频频调研各大连锁药店上市公 司，甚至有非医药的A股基金经理将十大重仓股席位几乎一半都安排在连锁药店赛道上，凸显出闭店潮强弩之 末时，基金经理已嗅到行业见底反转的机遇。 与A股基金经理策略相互呼应的是，虽然日本也在经历药店闭店潮，但今年一季度开始有全球著名的基金产品 在日本市场重仓四只连锁药店股票并大幅度获利，多个重仓中国连锁药店的A股基金经理则解释核心逻辑是挖 掘该赛道行业反转的可能性，并关注该赛道在经营场景中逐步增加慢病管理、宠物经济、保健品、药妆甚至彩 票等多元化业务带来的天花板突破机会。 闭店潮强弩之末，公募重新审视连锁药店赛道 在经历连续两年的闭店潮后，公募基金眼中的院外医药行业正迎来底部的战略性机会。 "连锁药店未来十年的需求是十分强劲的，消费支出场景可能不仅仅是用户进店买药，过去两年的关店潮会促 使市场集中度进一步提升，从而强化和增厚行业龙头的份额占有率和 ...

Core Insights - The chain pharmacy industry in 2024 is experiencing a significant slowdown, transitioning from a rapid expansion phase to one of reduced growth and declining profitability [2][3] - Six major private chain pharmacies reported revenue growth of less than 10%, with the highest being 8.01%, a stark contrast to previous years where many exceeded 20% [2] - Only Yifeng Pharmacy managed to achieve net profit growth, while the other five companies faced varying degrees of decline [2][5] Revenue and Profitability - Yifeng Pharmacy reported a revenue of 24.062 billion yuan with a net profit growth of 8.26%, becoming the only company to grow in a challenging environment [5] - Dazhenlin achieved the highest revenue of 26.497 billion yuan but saw a net profit decline of over 20% [5] - Laobaixing maintained a sales figure of 22.357 billion yuan, but its profits nearly halved [5] - Regional players like Shuyupingmin reported a loss of nearly 200 million yuan, while Jianzhijia's profits plummeted by about 70% [5] Store Expansion and Closure - Despite the overall industry challenges, the number of stores for major chain pharmacies continued to grow, with Dazhenlin adding 2,479 stores, Yifeng adding 1,434, and Laobaixing adding 1,703 [7] - The total number of closed pharmacies reached 25,114 in the first three quarters of 2024, with a growing trend in closures [5][6] Industry Challenges - The industry faces significant pressures from tightened healthcare policies, increased online competition, and changing consumer spending habits [3][8] - The competitive landscape has intensified, leading to price wars and promotional battles that compress profit margins [8] - Regulatory changes, such as stricter healthcare cost controls and increased compliance requirements, have further strained profitability [8][10] Strategic Responses - Companies are focusing on digital transformation and optimizing business structures to enhance efficiency and customer service [12] - Diversification into health products, beauty items, and health management services is becoming a strategic priority [12] - The integration of online and offline sales and services is seen as essential for future success, although it requires significant investment [12]

中信证券股份有限公司关于 益丰大药房连锁股份有限公司 2024 年度持续督导工作现场检查报告 根据《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等有关 法律、法规的规定，中信证券股份有限公司（以下简称"中信证券"、"保荐人"）作 为正在履行益丰大药房连锁股份有限公司（以下简称"益丰药房"、"上市公司"、 "公司"）持续督导工作的保荐人，对上市公司 2024 年度（以下简称"本持续督导 期间"）的规范运行情况进行了现场检查，现就现场检查的有关情况报告如下： 一、本次现场检查的基本情况 （一）保荐机构 丁元、赵岩 （三）现场检查时间 2025 年 4 月 14 日至 2025 年 4 月 16 日、2025 年 4 月 30 日 （四）现场检查人员 Liu XiaoLan、丁元、张强、李洋、黄中一 （五）现场检查手段 中信证券股份有限公司 现场检查人员对本持续督导期内发行人公司治理和内部控制情况、信息披露 情况、公司的独立性以及与控股股东、实际控制人及其他关联方资金往来情况、 募集资金使用情况、关联交易、对外担保、重大对外投资情况、经营状况等方面 进行了现场检查，具体检查内容详见本报告"二、本次现 ...

中信证券股份有限公司关于 益丰大药房连锁股份有限公司 2024 年度持续督导报告书 | 上市公司名称：益丰大药房连锁股份有限公司 | | | --- | --- | | 保荐人名称：中信证券股份有限公司 | | | 保荐代表人姓名：丁元 | 联系方式：021-20262071 | | 保荐代表人姓名：赵岩 | 联系方式：010-60834101 | 1、保荐人制定了持续督导工作制度，制定了相应的工作计划，明确了现场 检查的工作要求。 2、保荐人已与公司签订保荐协议，该协议已明确了双方在持续督导期间的 权利义务。 3、本持续督导期间，保荐人通过与公司的日常沟通、现场回访等方式开展 持续督导工作，并于 2025 年 4 月 14 日至 2025 年 4 月 16 日、2025 年 4 月 30 日 对公司进行了现场检查。 根据中国证券监督管理委员会《关于同意益丰大药房连锁股份有限公司向不 特定对象发行可转换公司债券注册的批复》（证监许可〔2024〕109 号），益丰 大药房连锁股份有限公司（以下简称"益丰药房"或"公司"）由主承销商中信证券 股份有限公司（以下简称"中信证券"或"保荐人"）采用余额包销方式，向社会 ...

Core Viewpoint - The financial reports of major chain pharmacy companies in A-shares indicate a challenging environment, with only one company, Yifeng Pharmacy, showing profit growth in 2024, while others faced declines, highlighting the difficulties of relying solely on store expansion for growth [1][3]. Financial Performance - In 2024, Yifeng Pharmacy achieved a revenue of 24.06 billion yuan, a year-on-year increase of 6.53%, and a net profit of 1.529 billion yuan, up 8.26% [4]. - In contrast, Shuyu Pingmin reported a revenue of 9.57 billion yuan, a 4.13% increase, but a net loss of 189 million yuan, marking a 241.9% decline compared to the previous year [3][4]. - Other companies like Laobaixing and Yixin Tang also experienced revenue declines, with Laobaixing's revenue at 22.358 billion yuan, down 0.36%, and a net profit decrease of 44.13% [4]. Store Expansion and Closure - Despite the financial struggles, the number of stores for the six major companies continued to grow in 2024, with Yifeng Pharmacy adding 2,512 stores, resulting in a total of 14,684 stores [5]. - Laobaixing reported a total of 15,277 stores, with a net increase of 1,703 stores during the year [6]. - However, the closure rate also increased, with Daclin closing 733 stores due to strategic adjustments [6]. Industry Challenges - The industry is facing significant challenges, including intensified competition, rising costs, and changing consumer purchasing habits, which are reflected in the declining net profits of listed chain pharmacies [4][8]. - The adjustment of medical insurance policies has also impacted the performance of chain pharmacies, leading to a shift in consumer purchasing behavior and a decrease in foot traffic to physical stores [8][9]. Future Directions - Experts suggest that the future development of chain pharmacies should focus on high-quality services rather than mere expansion, as the market becomes saturated [7]. - Companies are encouraged to enhance operational efficiency and improve service quality to remain competitive in a challenging environment [7][9].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's performance in 2024 met expectations, with total revenue reaching 24.06 billion yuan, a year-on-year increase of 6.53%, and net profit attributable to shareholders at 1.53 billion yuan, up 8.26% year-on-year [7] - The company is focusing on refined management to continuously enhance profitability [1] - The first quarter of 2025 showed a slight revenue increase of 0.64% to 6.01 billion yuan, with net profit attributable to shareholders rising by 10.51% to 449 million yuan [7] Financial Performance Summary - Total revenue projections for the company are as follows: 2023A: 22.59 billion yuan, 2024A: 24.06 billion yuan, 2025E: 26.92 billion yuan, 2026E: 29.61 billion yuan, 2027E: 32.57 billion yuan [1] - Net profit attributable to shareholders is projected to grow from 1.41 billion yuan in 2023A to 2.34 billion yuan in 2027E, reflecting a compound annual growth rate [1] - The company's earnings per share (EPS) is expected to increase from 1.16 yuan in 2023A to 1.93 yuan in 2027E [1] Operational Insights - The company achieved a sales gross margin of 40.12% in 2024, with a slight increase in net profit margin to 6.87% [7] - The total number of stores reached 14,694 by the first quarter of 2025, with a net increase of 1,434 stores in 2024 [7] - The company is focusing on regional expansion and improving operational efficiency, with a significant increase in non-pharmaceutical gross margins [7]